Neurocrine Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) said members of its management team will present at two investor conferences: a Jefferies Global Healthcare Conference fireside chat on November 18, 2025 at 12:00 PM GMT (7:00 AM ET) in London, and a Piper Sandler 37th Annual Healthcare Conference fireside chat on December 2, 2025 at 9:30 AM ET in New York.

Both presentations will be live webcast via the company's Investors page at www.neurocrine.com. Replays will be posted about one hour after each event and will be archived for approximately one month.

News Market Reaction

-0.30%

1 alert

-0.30% News Effect

On the day this news was published, NBIX declined 0.30%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:

• Jefferies Global Healthcare Conference. Fireside chat on Tuesday, November 18, 2025 at 12:00 PM GMT (7:00 AM ET) in London
• Piper Sandler 37^th Annual Healthcare Conference. Fireside chat on Tuesday, December 2, 2025 at 9:30 AM ET in New York, NY

The live webcasts can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook.  (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-302611943.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences (NBIX) present at the Jefferies Global Healthcare Conference?

The Jefferies fireside chat is scheduled for November 18, 2025 at 12:00 PM GMT (7:00 AM ET) in London.

When is Neurocrine Biosciences (NBIX) scheduled to present at the Piper Sandler 37th Annual Healthcare Conference?

The Piper Sandler fireside chat is scheduled for December 2, 2025 at 9:30 AM ET in New York.

How can investors watch Neurocrine Biosciences (NBIX) conference webcasts?

Live webcasts are available on Neurocrine's Investors page at www.neurocrine.com.

Will Neurocrine Biosciences (NBIX) provide replays of the investor presentations?

Yes. Replays will be posted about one hour after each event and archived for about one month.

Who from Neurocrine Biosciences (NBIX) will appear at the conferences?

Members of Neurocrine's management team will participate in the fireside chats.

Where are the Jefferies and Piper Sandler conferences taking place for Neurocrine Biosciences (NBIX)?

The Jefferies session is in London and the Piper Sandler session is in New York, NY.